Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial
- Autori: Cascio, A.; Colomba, C.; Di Rosa, D.; Salsa, L.; di Martino, L.; TITONE LANZA DI SCALEA, L.
- Anno di pubblicazione: 2001
- Tipologia: Articolo in rivista (Articolo in rivista)
- Parole Chiave: clarithromycin Mediterranean spotted fever
- OA Link: http://hdl.handle.net/10447/63391
Fifty-one children with Mediterranean spotted fever (MSF) were randomized to receive either clarithromycin, 15 mg/kg/day orally in 2 divided doses, or chloramphenicol, 50 mg/kg/day orally in 4 divided doses, for 7 days. Mean time to defervescence was 36.7 h in the clarithromycin group and 47.1 h in the chloramphenicol group (P=.047). Clarithromycin could be an acceptable therapeutic alternative to chloramphenicol and to tetracyclines for children aged <8 years with MSF